SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require…
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to…
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated…
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced…
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)HOUSTON, May…
TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce $80,000 research grant has been awarded…
KMHA DDR thorax inhale and exhale Images from a DDR acquisition (visualization of anatomy in motion) of a patient breathing,…
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to…
PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader…
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V:…